Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced...

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )

ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma

Dr Jonathan Ledermann - University College Hospital, London, UK

ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Dr Jonathan Ledermann - University College Hospital, London, UK )

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural...

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Checkmate 227: Final analysis for the non small cell lung cancer trial

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Checkmate 227: Final analysis for the non small cell lung cancer trial ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

PARP inhibitors for metastatic breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

KATHERINE trial updates for HER2-positive breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of...

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )

Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC

Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain

Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )

Association between tTMB and clinical outcomes with pembrolizumab alone in PD...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...

Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )

More from ecancer